Streetbeat News

Products Services

PUBM

PubMatic has partnered with Haleon to optimize video and CTV ads globally, enhancing supply path transparency and sustainability. This collaboration aims to improve efficiency and performance for Haleon's brands like Advil, Centrum, and Tums.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 8:02 am

INCY

Incyte has unveiled promising results for its CDK2 inhibitor, INCB123667, in treating advanced solid tumors, including ovarian cancer. The data supports a pivotal trial in ovarian cancer set for 2025 and plans for combination treatments.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 7:58 am

MASI

QCOM

Masimo and Qualcomm have partnered to launch a next-generation smartwatch platform for OEMs, enhancing Wear OS capabilities. This collaboration aims to integrate Masimo's health monitoring technology with Qualcomm's Snapdragon Wear platform.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 7:50 am

GOOG

MASI

Masimo has partnered with Google to develop a comprehensive smartwatch reference platform for OEMs using Wear OS. This platform will integrate Masimo's biosensing capabilities with Google's software expertise.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 7:49 am

NTRA

Natera's Signatera test shows significant predictive power for overall survival in colorectal cancer patients, according to new data from the GALAXY study presented at ESMO. The test indicates a nearly 10x advantage in survival at 36 months based on ctDNA status and a 50% reduction in death risk for Signatera-positive patients treated with ACT.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 7:46 am

MGNX

MacroGenics presented promising Phase 2 data for Vobra Duo in the TAMARACK study at ESMO 2024, showing encouraging antitumor activity. The company plans an investor call to discuss the results and provide a corporate update.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 7:31 am

ME

23andMe Therapeutics has released Phase 2 findings for its 23ME-00610 trial, showing clinical benefits in clear-cell renal-cell carcinoma. The study highlights the potential of CD200 and human genetics as biomarkers for patient selection.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 7:28 am

AAPL

DIS

NFLX

WBD

The 76th Primetime Emmy Awards highlighted the success of FX, a subsidiary of Disney, with 'Shōgun' and 'The Bear' winning multiple awards. Disney's FX led with 36 awards, surpassing its previous record. Netflix, HBO, and Apple TV+ also secured significant wins.

Portfolio Pulse from Ananya Gairola

September 16, 2024 | 7:24 am

EXEL

Exelixis, Inc. presented final Phase 3 CONTACT-02 study results at ESMO 2024, showing overall survival data for cabozantinib in combination with atezolizumab in metastatic prostate cancer patients.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 7:19 am

LNTH

Lantheus presented positive Phase 3 SPLASH trial results for PSMA-positive metastatic prostate cancer at ESMO 2024. The study met its primary endpoint, showing significant improvement in radiographic progression-free survival and overall response rate. Patients also showed improved health-related quality of life.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 7:14 am